Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 260-268

  Zhao, Lan Juan ^a   Wang, Wen ^a   Liu, Yuan ^a,b   Ren, Hao ^a   Qi, Zhong Tian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b General Hospital of the Chengdu Military Command   (China)

Author keywords

ERK; Hepatitis C virus; Ribavirin; STAT

Indexed keywords

ALPHA INTERFERON; INTERFERON REGULATORY FACTOR 9; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE TYK2; RAF PROTEIN; RIBAVIRIN; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HEPATOCYTES; HUMANS; MAP KINASE SIGNALING SYSTEM; RIBAVIRIN; RNA, VIRAL; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VIRAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84867583845     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.002     Document Type: Article

References (39)

1. Avolio S., Summa V. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease. Curr. Top. Med. Chem. 2010, 10:1403-1422.
2. Baiocchi L., De Leonardis F., Delle Monache M., Nosotti L., Conti R.L., Lenci I., Carbone M., Di Paolo D., Cucchiarelli S., Angelico M. Plasma/erythrocyte ribavirin ×100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response. Antivir. Ther. 2010, 15:633-639.
3. Borden K.L., Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?. Leuk. Lymphoma 2010, 51:1805-1815.
4. Brochot E., Duverlie G., Castelain S., Morel V., Wychowski C., Dubuisson J., François C. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir. Ther. 2007, 12:805-813.
5. Chen Q.L., Zhu S.Y., Bian Z.Q., Zhao L.J., Cao J., Pan W., Qi Z.T. Activation of p38 MAPK pathway by hepatitis C virus E2 in cells transiently expressing DC-SIGN. Cell Biochem. Biophys. 2010, 56:49-58.
6. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
7. Feld J.J., Lutchman G.A., Heller T., Hara K., Pfeiffer J.K., Leff R.D., Meek C., Rivera M., Ko M., Koh C., Rotman Y., Ghany M.G., Haynes-Williams V., Neumann A.U., Liang T.J., Hoofnagle J.H. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010, 139:154-162.
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
9. Fujii N., Yokosawa N., Shirakawa S. Suppression of interferon response gene expression in cells persistently infected with mumps virus, and restoration from its suppression by treatment with ribavirin. Virus Res. 1999, 65:175-185.
10. Homma M., Matsuzaki Y., Inoue Y., Shibata M., Mitamura K., Tanaka N., Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin. Gastroenterol. Hepatol. 2004, 2:337-339.
11. Hoofnagle J.H., Lau D., Conjeevaram H., Kleiner D., Di Bisceglie A.M. Prolonged therapy of chronic hepatitis C with ribavirin. J. Viral. Hepat. 1996, 3:247-252.
12. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298:1911-1912.
13. Khan F., Peltekian K.M., Peterson T.C. Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. J. Interferon Cytokine Res. 2008, 28:643-651.
14. Kökény S., Papp J., Weber G., Vaszkó T., Carmona-Saez P., Oláh E. Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res. 2009, 29:1971-1980.
15. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
16. Li W., Shen F., Weber G. Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells. Oncol. Res. 1999, 11:243-247.
17. Maynard M., Pradat P., Gagnieu M.C., Souvignet C., Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir. Ther. 2008, 13:607-611.
18. McHutchison J.G., Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 1999, 19(Suppl. 1):57-65.
19. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nature 2007, 5:453-463.
20. Mori K., Ikeda M., Ariumi Y., Dansako H., Wakita T., Kato N. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res. 2011, 157:61-70.
21. Ogbomo H., Michaelis M., Altenbrandt B., Doerr H.W., Cinatl J. A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function. Biochem. Pharmacol. 2010, 79:188-197.
22. Reddy K.R., Nelson D.R., Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J. Hepatol. 2009, 50:402-411.
23. Schindler C., Levy D.E. Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 2007, 282:20059-20063.
24. Simone O., Tortorella C., Zaccaro B., Napoli N., Antonaci S. Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. J. Clin. Immunol. 2010, 30:556-565.
25. Stevenson N.J., Murphy A.G., Bourke N.M., Keogh C.A., Hegarty J.E., O'Farrelly C. Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 2011, 6:e27866.
26. Su W.C., Liu W.L., Cheng C.W., Chou Y.B., Hung K.H., Huang W.H., Wu C.L., Li Y.T., Shiau A.L., Lai M.Y. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett. 2009, 583:2793-2798.
27. Tan K., Culjkovic B., Amri A., Borden K.L. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem. Biophys. Res. Commun. 2008, 375:341-345.
28. Taylor M.W., Grosse W.M., Schaley J.E., Sanda C., Wu X., Chien S.C., Smith F., Wu T.G., Stephens M., Ferris M.W., McClintick J.N., Jerome R.E., Edenberg H.J. Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J. Interferon Cytokine Res. 2004, 24:107-118.
29. Taylor M.W., Tsukahara T., Brodsky L., Schaley J., Sanda C., Stephens M.J., McClintick J.N., Edenberg H.J., Li L., Tavis J.E., Howell C., Belle S.H. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J. Virol. 2007, 81:3391-3401.
30. Thomas E., Feld J.J., Li Q., Hu Z., Fried M.W., Liang T.J. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53:32-41.
31. Tong Y., Zhu Y., Xia X., Liu Y., Feng Y., Hua X., Chen Z., Ding H., Gao L., Wang Y., Feitelson M.A., Zhao P., Qi Z.T. Tupaia CD81, SR-BI, Claudin-1, and Occludin support hepatitis C virus infection. J. Virol. 2011, 85:2793-2802.
32. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., Kanamori A., Atsumi H., Nakano S., Arakawa T., Honda T., Hayashi K., Katano Y., Goto H. Correlation of serum ribavirin concentration with pretreatmentrenal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin. J. Viral. Hepat. 2008, 15:651-658.
33. Vallée S., Fouchier F., Braguer D., Marvaldi J., Champion S. Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). Eur. J. Pharmacol. 2000, 404:49-62.
34. Younossi Z.M., Limongi D., Stepanova M., Pierobon M., Afendy A., Mehta R., Baranova A., Liotta L., Petricoin E. Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). J. Proteome Res. 2011, 10:774-779.
35. Zhang Y., Jamaluddin M., Wang S., Tian B., Garofalo R.P., Casola A., Brasier A.R. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 2003, 77:5933-5947.
36. Zhao L.J., Wang L., Ren H., Cao J., Li L., Ke J.S., Qi Z.T. Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Exp. Cell Res. 2005, 305:23-32.
37. Zhao L.J., Zhang X.L., Zhao P., Cao J., Cao M.M., Zhu S.Y., Liu H.Q., Qi Z.T. Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. J. Leukoc. Biol. 2006, 80:424-432.
38. Zhao L.J., Zhao P., Chen Q.L., Ren H., Pan W., Qi Z.T. Mitogen-activated protein kinase signaling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection. Cell Prolif. 2007, 40:508-521.
39. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102:9294-9299.